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SHUNT SURGERY VERSUS ENDOSCOPIC SCLEROTHERAPY
FOR LONG-TERM TREATMENT OF VARICEAL BLEEDING
Early Results of a Randomized Trial
Rikkers, L.F., Burnett, D.A., Volentine, G.D., Buchi, K.N. and Cormier
R.A. (1987) Annals of Surgery, 206,261-271.
ABSTRACT
In September 1982, a prospective randomized trial comparing shunt surgery and
endoscopic sclerotherapy for the elective management of variceal hemorrhage in
patients with cirrhosis was initiated. Twenty-seven patients have received shunts
(distal splenorenal 23, nonselective 4) and 30 patients have had chronic
sclerotherapy. Eighty-six per cent of patients had alcoholic cirrhosis and 33% were
Child’s class C. After a mean follow-up of 25 months, 19% of shunt and 57% of
sclerotherapy patients have had rebleeding (p 0.003). Kaplan-Meier survival
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analysis reveals similar 2-year survival rates for shunt (65%) and sclerotherapy (61%)
groups. Only two of 10 sclerotherapy failures have been salvaged by surgery. Post-
therapy quantitative hepatic function, frequency of encephalopathy, and cumulative
medical costs were similar for both groups. Hepatic portal perfusion and portal
pressure at I year were better maintained by sclerotherapy than by distal splenorenai
shunt. In conclusion, endoscopic sclerotherapy and shunt surgery provide similar
results with respect to survival, hepatic function, frequency of encephalopathy, and
costs. Sclerotherapy is an acceptable, but not superior, alternative to shunt surgery
for treatment of variceal hemorrhage.
PAPER DISCUSSION
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Repeated sclerotherapy is currently the most widely practised therapeutic measure
in the long-term management of patients after a variceal bleed. It effectively
eradicates oesophageal varices in most patients and after eradication recurrent
variceal bleeding is significantly reduced1-5. Improvement in survival remains
unproven particularly if the best available therapy, including sclerotherapy, is used
for acute variceal bleeds when they occur6. Although repeated sclerotherapy is
usually performed on an outpatient basis using a flexible endoscope without an
anaesthetic, it is not without problems. Life long follow-up with repeated injections
are required and complications become cumulative with time. Those patients who
survive for prolonged periods place a major load on the hospital’s resources.
Thus other forms of long-term management are continually under review. The
most commonly used alternative procedure today is a porto-systemic shunt with the
selective distal splenorenal shunt being the most popular. A successful shunt
effectively prevents recurrent variceal bleeding but is unfortunately associated with
unpredictable morbidity in the form of hepatic encephalopathy as well as mortality.
The selective distal splenorenal shunt is favoured but is also not without problems.
Of the six completed controlled trials7-12 comparing the distal splenorenal shunt with
conventional shunts only three have demonstrated a lesser immediate
encephalopathy rate8’9’12. Although the maintenance of prograde portal vein flow is
one of the theoretical advantages of a Warren shunt, which should lead to better
preservation of liver function, not all patients with a Warren shunt maintain
prograde portal perfusion11’13. This applies particularly to patients with alcoholic
cirrhosis. Further problems with this shunt include its not being applicable to all
patients especially those with marked ascites which is difficult to control and patients
in poor general condition. Also survival in alcoholic cirrhosis is worse than in non-
alcoholic cirrhosisTM. These problems and reservations regarding both sclerotherapy
and the popular distal splenorenal shunt make it vital that controlled trials be
conducted.
The controlled trial under review undertaken by Rikkers et al demonstrated no
difference between shunts and sclerotherapy. Because of the small number of
patients included a type II error may have occurred. Thus, although no difference
was found, with a greater number of patients and longer follow-up a difference might
have been demonstrated.
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splenorenal shunt. The first, from Warren’s group at Emory, showed significantly
improved survival in patients receiving sclerotherapy, when backed up by distal
splenorenal shunt for the sclerotherapy failures (31% of patients) 15. The patients
undergoing sclerotherapy had a higher rebleed rate than those undergoing a distal
splenorenal shunt while, on the other hand, sclerotherapy was associated with
significantly improved liver function compared with shunts. The third trial showed
no difference in survival between the sclerosed and shunted patients16. This group
concluded that endoscopic sclerotherapy was a good alternative to splenorenal
shunting in the elective treatment of oesophageal variceal bleeding, especially in
patients prone to develop hepatic encephalopathy.
Once again, as with so many portal hypertension studies, controlled trials have
resulted in conflicting results. The differences in these trials require further
evaluation. There were subtle differences in the design of all three trials as well as
variations in technique and in the types of patients included. Comparing Warren’s
and Rikkers’ trial, Rikkers was unable to salvage the failures of sclerotherapy by
shunt surgery. Four patients had salvage surgery and only two survived. The main
difference in survival was that there was a higher survival rate for the sclerosed
patients (including the shunt salvage patients) in the Emory trial15 whereas the
shunted patients in both groups had a similar survival. Sclerosed patients tended to
die of bleeding while shunted patients died of liver failure. An important finding in
both studies was that rebleeds after sclerotherapy were predominantly from gastric
varices or portal hypertensive gastropathy. Such patients could probably only be
salvaged by shunting and the early shunting of the sclerotherapy failures in Warren et
al’s trial was probably an important factor.
The Barcelona trial of Teres et al6 contained a greater number of patients (112
patients), the sclerotherapy technique used was different including the use of
ethanolamine oleate as sclerosant, and the distal splenorenal shunt was modified by
performing it through a retroperitoneal approach without porto-azygous
disconnection. This modification has been correctly criticised as not being a true
distal splenorenal shunt. Despite careful analysis the reasons for the differences in
outcome in these three trials remain obscure. Rikkers contends that somewhat better
risk patients were included in the Warren study5. All the papers suggest that
sclerotherapy is better than shunting in poor risk patients. The author believes that a
reasonable approach would be to use repeated sclerotherapy as the first line
treatment in all patients, but that any evidence of failure of sclerotherapy mandates
a more radical surgical approach. The trials under discussion only considered
shunting particularly the distal splenorenal shunt. Other trials are underway
(including one in Cape Town) comparing sclerotherapy with extensive
devascularisation and transection operations. When completed, they may indicate
subsets of patients in whom these procedures may be preferable to shunts.
The trials under discussion all considered long-term therapy only and did not
address the role of shunts or sclerotherapy in emergency therapy. In a controlled trial
of emergency therapy in a selected group of poor risk patients Cello et al7 have
concluded that, although sclerotherapy is as good as end to side portacaval shunting
in the acute management of variceal haemorrhage, sclerotherapy patients in whom
varices are not obliterated and bleeding continues should be considered for elective
shunt surgery. The costs and long-term survival did not differ significantly in the two
groups.
Clearly the bottom line has yet to be written. Further carefully conducted88 HPB INTERNATIONAL
controlled trials are essential in this important and difficult area. Finally, present
evidence indicates that liver transplantation is a better therapeutic option than either
sclerotherapy or shunts in poor risk patients, particularly those with non-alcoholic
cirrhosis. This was emphasied by Iwatsuki in the discussion of the paper under
review. John Terblanche
Dept. of Surgery
Univ. of Cape Town Medical School
Cape Town, South Africa
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